

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:

File Information Unit, Room 2E04
2900 Crystal Drive
Arlington, VA 22202-3514

Telephone: (703) 308-2733

In re Application of _____

Application Number

07/566,977

Filed

8/13/90

Paper No. #29

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. _____, page, _____ line _____

United States Patent Number 5623065, column _____, line, _____ or

WIPO Pub. No. _____, page _____, line _____

Related Information About Access to Applications Maintained in the Image File Wrapper System (IFW) and Access to Pending Applications in General


A member of the public, acting without a power to inspect, cannot order applications maintained in the IFW system through the FIU. If the member of the public is entitled to a copy of the application file, then the file is made available through the Public Patent Application Information Retrieval system (Public PAIR) on the USPTO internet web site (www.uspto.gov). Terminals that allow access to Public PAIR are available in the Public Search Room. The member of the public may also be entitled to obtain a copy of all or part of the application file upon payment of the appropriate fee. Such copies must be purchased through the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)).

For published applications that are still pending, a member of the public may obtain a copy of:

the file contents; the pending application as originally filed; or any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of: the file contents; the pending application as originally filed; or any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of the pending application as originally filed.



Signature



Typed or printed name

Registration Number, if applicable

703-553-0000

Telephone Number

RECEIVED
JUL 29 20097/29/09
Date

FOR PTO USE ONLY

Approved by: 

(initials)

Unit: F.I.U.

This collection of information is required by 37 CFR 1.11 and 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Room 2E04, 2900 Crystal Drive, Arlington, Virginia.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



US05523065A

United States Patent [19]

Cook et al.

[11] Patent Number: 5,623,065

[45] Date of Patent: Apr. 22, 1997

[54] **GAPPED 2' MODIFIED OLIGONUCLEOTIDES**[75] Inventors: **Phillip D. Cook, Vista; Brett P. Monia, Carlsbad, both of Calif.**[73] Assignee: **Isis Pharmaceuticals, Inc., Carlsbad, Calif.**[21] Appl. No.: **244,993**[22] PCT Filed: **Dec. 23, 1992**[86] PCT No.: **PCT/US92/11339**§ 371 Date: **Jun. 21, 1994**§ 102(e) Date: **Jun. 21, 1994**[87] PCT Pub. No.: **WO93/11339**PCT Pub. Date: **Jul. 8, 1993****Related U.S. Application Data**

[63] Continuation-in-part of Ser. No. 814,961, Dec. 24, 1991, abandoned, and Ser. No. 566,977, Aug. 13, 1990, abandoned.

[51] Int. Cl.⁶ **C07H 21/00; C07H 21/02; C07H 21/04**[52] U.S. Cl. **536/23.1; 536/23.2; 536/23.5; 536/23.51; 536/23.52; 536/23.53; 536/25.1; 536/25.2; 435/91.1; 435/91.2; 435/91.5; 935/6; 935/9; 935/10**[58] Field of Search **514/44; 536/23.1; 536/23.2, 23.5, 23.51, 23.52, 23.53, 25.1; 25.2; 435/91.1, 91.2, 91.4, 91.5; 935/9, 6, 10**[56] **References Cited****U.S. PATENT DOCUMENTS**

4,867,187	9/1989	Duck	435/6
4,908,307	3/1990	Rodland et al.	435/6
5,013,830	5/1991	Ohtsuka et al.	536/25.1
5,034,506	7/1991	Summerton et al.	528/391
5,134,066	7/1992	Rogers et al.	435/91.3
5,149,797	9/1992	Pederson et al.	536/23.1
5,220,007	6/1993	Pederson et al.	536/23.1
5,256,775	10/1993	Froehler	536/25.6
5,366,878	11/1994	Pederson et al.	435/91.3
5,403,711	4/1995	Walder et al.	435/6
5,466,786	11/1995	Buhr et al.	536/26.26

FOREIGN PATENT DOCUMENTS

2017369	11/1990	Canada
*260032	8/1987	European Pat. Off.
365627B1	3/1989	European Pat. Off.
*0339842	4/1989	European Pat. Off.
*0339330	11/1990	European Pat. Off.
3915462	9/1990	Germany
4110085	10/1992	Germany
3-240795	of 1991	Japan
89/05358	6/1989	WIPO
*WO90/15814	6/1990	WIPO
*WO91/06556	10/1990	WIPO
*WO91/15499	4/1991	WIPO
*WO91/12323	8/1991	WIPO
*WO94/02498	2/1994	WIPO
*WO92/07065	9/1994	WIPO

OTHER PUBLICATIONS

Block et al. 1988 Gene 72, 349-360.

Cormier et al. 1988 Nuc. Acids Res. 16(10), 4583-4594.

Uhlmann et al. 1990 Chemical Reviews 90(4), 544-584.

Ikehara et al. 1977 Nuc. Acids Res. 4(12): 4249-4260.

Berkowitz et al. 1973 J. Medicinal Chemistry, 16(2): 813-814.

Kawasaki et al. 1991 (Jan.) "Synthesis and Biophysical Studies of 2'-dRIBO-F Modified Oligonucleotides", Conference on Nucleic Acid Therapeutics, Clearwater, FL.

Agrawal, S. et al., "Oligodeoxynucleoside Phosphoramidates and Phosphorothioates as Inhibitors of Human Immunodeficiency Virus" *Proc. Natl. Acad. Sci. USA* 1988 85, 7079-7083.

Augustyns, et. al., "Influence of the Incorporation of (S)-9-(3,4-dihydroxy-butyl)Adenine on the Enzymatic Stability and Base-Pairing Properties of Oligodeoxynucleotides" *Nucleic Acids Research* 1991, 19, 2587-2593.

Beaton, et. al., Chapter 5, Synthesis of oligonucleotide phosphorodithioates, p. 109, *Oligonucleotides and Analogs, A Practical Approach*, Eckstein, F., Ed.; The Practical Approach Series, IRL Press, New York, 1991, pp. 109-135.

Borthwick, et al., "Synthesis of Chiral Carbocyclic Nucleosides" *Tetrahedron* 1992, 48, 571-623.

Brill et al., "Synthesis of Deoxydinucleoside Phosphorodithioates", *J. Am. Chem. Soc.* 1991 113, 3972-3980.

Cohen in *Oligonucleotides: Antisense Inhibitors of Gene Expression*, CRC Press, Inc., Boca Raton, FL (1989), pp. 1-255.

Dagle et al., "Physical properties of oligonucleotides containing phosphoramidate-modified internucleoside linkages", *Nucleic Acids Research* 1991 19, 1805-1810.

Dagle et al., "Targeted degradation of mRNA in *Xenopus* oocytes and embryos directed by modified oligonucleotides: studies of An2 and cyclin in embryogenesis", *Nucleic Acids Research* 1990 18, 4751-4757.

Dagle et al., "Pathways of Degradation and Mechanism of Action of Antisense Oligonucleotides in *Xenopus laevis* Embryos", *Antisense Research and Development* 1991 1, 11-20.

Debart et al., "Intermolecular Radical C-C Bond Formation: Synthesis of a Novel Dinucleoside Linker for Non-anionic Antisense Oligonucleosides", *Tetra. Ltrs.* 1992 33, 2645-2648.

(List continued on next page.)

Primary Examiner—Christopher S. F. Low
Attorney, Agent, or Firm—Woodcock Washburn Kurtz Mackiewicz & Norris

[57] **ABSTRACT**

Oligonucleotides and other macromolecules are provided that have increased nuclease resistance, substituent groups for increasing binding affinity to complementary strand, and subsequences of 2'-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H enzyme. Such oligonucleotides and macromolecules are useful for diagnostics and other research purposes, for modulating protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to antisense therapeutics.

19 Claims, 2 Drawing Sheets

D-1